The double-blind, randomised, controlled trial will evaluate WB001, a Software as a Medical Device (SaMD) based Cognitive Behavioural Therapy (CBT) program for the treatment of mild to moderate PPD.
Actively recruiting women aged 22 to 45 years old who have given birth in the last three months and are experiencing mild to moderate PPD, the purpose of the study is to determine if, for women diagnosed with PPD, WB001 as an adjunct to Treatment as Usual (TAU) can reduce symptoms of depression, compared to an educational control with adjunctive TAU at the end of eight weeks of treatment – as measured by clinically validated HAM-D6 scale, which is an assessment of symptoms of depression, such as depressed mood, guilt, psychomotor retardation, psychic anxiety, and general somatic symptoms.
